HUMAGEN PIPETS

MEDICULTMEDIA

MIDATLANTICDEVICES

ORIGIO a/s- A world leader in Assisted Reproductive Technology Jesper Funding Andersen, CEO

ProInvestor, Life Science Seminar 2012April 11, 2012

www.origio.com

Ticker (OSE): ORO

HUMAGEN PIPETS

MEDICULTMEDIA

MIDATLANTICDEVICES

2

Forward-Looking Statements

This presentation includes forward-looking statements regarding ORIGIO a/s, including projections and expectations, which involve risk and uncertainty. Such statements are included without any guarantee as to their future realization. Although ORIGIO believes that the expectations regarding the Company reflected in such forward-looking statements are based on reasonable assumptions, no assurance can be given that such projections will be fulfilled. Any such forward-looking statement must be considered along with the knowledge that actual events or results may vary materially from such predictions due to, among other things, political, economic, financial or legal changes in the markets in which ORIGIO does business, and competitive developments or risks inherent to the Company’s business plans. Many of these factors are beyond ORIGIO’s ability to control or predict. Given these uncertainties, readers are cautioned not to place undue reliance on any forward-looking statements. The Company does not intend, and does not assume any obligation, to update the forward-looking statements included in this presentation as of any date subsequent to the date hereof.

HUMAGEN PIPETS

MEDICULTMEDIA

MIDATLANTICDEVICES

3

ORIGIO at a glance A world leader in Assisted Reproductive Technology (ART) solutions

• ART – a highly attractive growth market• Global ART market holds large opportunities• Number of mega trends set to accelerate growth in future

• ORIGIO – The largest focused ART player world-wide • A med-tech company with attractive financial performance• Broad product portfolio (consumables and equipment) for ART

treatment• Direct sales in more than 26 markets and strong network of

distribution partners• Strong pipeline of R&D projects with focus on improving “Baby-

take-home” rate

HUMAGEN PIPETS

MEDICULTMEDIA

MIDATLANTICDEVICES

Our Vision/Mission

Vision: To make the #1 dream of every infertile couple come true

Mission: We deliver leading, innovative ART solutions to the benefit of families

ARC

Our products play an important role for a baby born every 4 minutes.

More than 150,000 babies/year are born using ORIGIO products.

HUMAGEN PIPETS

MEDICULTMEDIA

MIDATLANTICDEVICES

5

Agenda

Assisted Reproductive Technology – a highly attractive growth market

ORIGIO – a world leader in Assisted Reproductive Technology

Summary

HUMAGEN PIPETS

MEDICULTMEDIA

MIDATLANTICDEVICES

6

Megatrends to accelerate growth in ART

Total fertility rates too low in many developed

countries to sustain population

Population growth (in less developed

countries) → more infertile couples

Wealth creation in less developed

countries

Sperm quality on decline

Untreated sexually transmitted infections can result in infertility

Increased use of fertility preservation (disease or

oocyte banking)

Increasing maternal age at first pregnancy

Obesity (and eating disorders) reducing

female (and male) fertility

= Illustrative graphs on the following slides

HUMAGEN PIPETS

MEDICULTMEDIA

MIDATLANTICDEVICES

7

Low total fertility rates put pressure on the demographic balance

Source: CIA – The World Factbook, 2011 estimate

No

. o

f c

hil

dre

n b

orn

pe

r fe

ma

le a

ge

d 1

5-4

9 y

ea

rrs

…..a country has to score a balance of 2.1 to reproduce itself. If not, it can (1) ’accept’ population decline

(2) ’open up borders’ (3) ’incentivise’ - IVF can make a difference

Demographic balance 2.1

HUMAGEN PIPETS

MEDICULTMEDIA

MIDATLANTICDEVICES

8

Maternal age at first pregnancy increasing

Average age of mother at first birth

Source: Eurostat (2010) and United Nations Statistical Division (2010) and National Statistical Offices

Female fertility drops sharply from early 30’ies

Source: 2008 Assisted Reproductive Technology Success Rates. US National Summary and Fertility Clinic Reports

HUMAGEN PIPETS

MEDICULTMEDIA

MIDATLANTICDEVICES

The middle- and upper classes in less developed countries are growing rapidly.Hence, the number of couples that can afford IVF treatments

will grow at a fast pace

Wealth creation in less developed countriesIndia - example of an emerging market opportunity

9

HUMAGEN PIPETS

MEDICULTMEDIA

MIDATLANTICDEVICES

10

Large potential for improving IVF success rate

88%81%

34%28%

21%

0%10%

20%30%

40%50%60%

70%80%

90%100%

Retrieval Transfer Clin.pregnancy

Live birth Singleton lifebirth

US success rates for fresh non-donor eggs – per cycle started

Source: CDC and HFEA 2005 data (published 2008)

UK data (fresh and frozen, donor or own eggs): 22% 16%

HUMAGEN PIPETS

MEDICULTMEDIA

MIDATLANTICDEVICES

1111

Agenda

Assisted Reproductive Technology – a highly attractive growth market

ORIGIO – a world leader in Assisted Reproductive Technology

Summary

HUMAGEN PIPETS

MEDICULTMEDIA

MIDATLANTICDEVICES

12

ORIGIO - the largest focused ART player world-wide

ART media, pipets, needles/

catheters, devices,

equipment

ART media, pipets,

needles/ catheters

ART media, pipets, needles/

catheters, devices, incubator

ART media, needles/ catheters

ART media, needles/ catheters

ART media, workstations

IVF products turnover – 2011 estimates

Source: ORIGIO estimate. Cook, Irvine and Sage are all parts of larger conglomerates

The largest players within hormones for

fertility treatment includeMerckSerono, Ferring

and Merck

Product groups

HUMAGEN PIPETS

MEDICULTMEDIA

MIDATLANTICDEVICES

13

ORIGIO’s consistent growth strategyTransformation along 3 key dimensions

Regulatory demands on IVF devices increases strongly

HUMAGEN PIPETS

MEDICULTMEDIA

MIDATLANTICDEVICES

14

Strong geographical presence

Key geographical steps

• 2005: Italy• 2005: Germany (DACH)• 2005(-10): Australia• 2006: Spain• 2006(-08): USA• 2008: Benelux• 2008: China• 2010: Russia• 2012: Japan• 2012: India

14

Globally leading sales infrastructure with own presence in key IVF markets… and strong network of distribution partners covering 100+ countries

HUMAGEN PIPETS

MEDICULTMEDIA

MIDATLANTICDEVICES

15

ORIGIO sells direct in most key markets

Source: ORIGIO estimate

ORIGIO sells direct in more than 26 markets representing, in total, around ⅔ of the global IVF market

HUMAGEN PIPETS

MEDICULTMEDIA

MIDATLANTICDEVICES

16

Product range expanded One company with 3 strong product brands

ORIGIO MidAtlantic Devices: Provides innovative devices, equipment, and services to IVF labs

ART ’Total’ Supplier – US #1ART Disposables - Global

ORIGIO MediCult Media: Leads the way in the development and provision of specialized and innovative ART media.

ART Media – Global #1

ORIGIO Humagen Pipets: Focuses on the creation of the highest quality specialty pipets and microtools for IVF

ART Micropipets – Global #1

Global equipment line after 51% stake in ORIGIO ScanLab Equipment

Acquired 100% of US-based PMD containing state-of-art automation technology for micropipettes

Broad product portfolio fulfilling most IVF laboratory needs2007

2008

2010

2010

Acquired MDT Artworks B.V. – Dutch manufacturer of IVF needles and catheters

2011

HUMAGEN PIPETS

MEDICULTMEDIA

MIDATLANTICDEVICES

Enlargement of ORIGIO’s product portfolio during 2011Embryo transfer catheters and oocyte retrieval needles

Ovarian hormone stimulation

Egg retrieval

Fertilization(IVF or ICSI)

Embryoculture

Cryo preservation

Embryo transfer catheters

Embryo transfer

Oocyte retrieval needles

Previous ORIGIO product offering(media, pipets, devices, equipment)

Current ORIGIO product offering(fulfilling most IVF laboratory needs)

17

HUMAGEN PIPETS

MEDICULTMEDIA

MIDATLANTICDEVICES

18

Strong ART pipeline – focus on improving “Baby-take-home” rate

Preclinical documentation (H2 2012)

Pilot human implantation data (H2 2012)

Bovine data (H1 2012)

Exploratory human data(Q2/Q3 2013)

FDA clearance (H2 2012)*

Next milestoneProductType RegulatoryProof-of-concept

Clinical

EmbryoSure®

SMARTStart™

EmbryoGen®

Iloprost

GM-CSF day 5

Culture media, day 3

Culture media, day 5

Culture media, day 5

EmbryoSelection

Microfluidics

*Launched in Europe, Asia, Middle East and Canada in H2 2011. Obtained CE-mark in August 2011

HUMAGEN PIPETS

MEDICULTMEDIA

MIDATLANTICDEVICES

Live birth rates support significant effect from EmbryoGen® in patients with previous miscarriage

Average number of embryos transferred: EmbryoGen®: 1.55; Control 1.56Number of transfer cycles: EmbryoGen®: 142; Control 147Twinning rate similar in the two groups

29.6

17.4

23.1+28%

+28%p=0.02

p=0.03

Live birth rate in patients with previous miscarriage

19

22.3

HUMAGEN PIPETS

MEDICULTMEDIA

MIDATLANTICDEVICES

20

EmbryoGen® succesfully launched in Q3 2011

• EmbryoGen® successfully launched and already sold in more than 40 countries throughout Europe, Asia, Middle-East and Africa*

• In general, at least 20% of all pregnancies end in miscarriage, and the primary target group for EmbryoGen® is thus believed to be more than 200,000 cycles per year

• Culture media makes up <2% of the IVF treatment, but impacts the “Baby-take-home” rate significantly

• EmbryoGen® can obtain premium pricing and still reduce the average cost per child conceived via ART due to lower average number of cycles to become pregnant

• ORIGIO has world-wide exclusive rights for human use of ART media containing GM-CSF

*Launch in the US expected in the second half of 2012

HUMAGEN PIPETS

MEDICULTMEDIA

MIDATLANTICDEVICES

Growth in key operational financials 2005 – 2011

Revenue EBITDA before special items

CAGR: 31%

21

• Strong revenue growth

• Increasing EBITDA-margin

• Positive operating cash flow despite

high growth

Operating cash flow

HUMAGEN PIPETS

MEDICULTMEDIA

MIDATLANTICDEVICES

22

ORIGIO group growth drivers

Regions

DKK million

FY

2011

Organic growth*

2011

Europe 162 13%

Americas 99 18%

ROW 109 36%

Total 370 20%

Products

DKK million

FY

2011

Organic growth*

2011

Disposables 298 13%

Equipment 72 60%

Total 370 20%

* Constant currency

HUMAGEN PIPETS

MEDICULTMEDIA

MIDATLANTICDEVICES

23

Recent Shareprice developmentORIGIO vs. Indices

• Listed on the Oslo Stock Exchange since 1996

• Market cap of approximately NOK 600 million

• Included in the liquidity category ‘OB Match’• Comprising shares with a minimum of 10

official trades per day

• Approximately 1,600 shareholders including several Norwegian (and one Danish) Blue Chip institutional investors

• Orkla• William Demant Invest• Skagen Vekst• Storebrand • MP Pensjon

HUMAGEN PIPETS

MEDICULTMEDIA

MIDATLANTICDEVICES

2424

Agenda

Assisted Reproductive Technology – a highly attractive growth market

ORIGIO – A world leader in Assisted Reproductive Technology

Summary

HUMAGEN PIPETS

MEDICULTMEDIA

MIDATLANTICDEVICES

25

ORIGIO - a med-tech company well positioned for continued profitable growth

• Assisted Reproductive Technology – a highly attractive growth market

• World leading, focused ART player with broad product portfolio, direct

presence in key markets and strong pipeline of new technologies

• Sound financial platform and solid financial outlook for 2012• Revenue of approximately DKK 450 million• Organic growth in constant currencies of minimum 10%• EBITDA margin before special items of 15-17%

• Consistent strategic focus with a clear growth strategy

HUMAGEN PIPETS

MEDICULTMEDIA

MIDATLANTICDEVICES

26

“At the end of the day, it’s all about life; the opportunity for helping IVF professionals

to create new life for families. Life is everything. That's what we stand for “